Cart
sales@molnova.com
Betamipron
CAS No. 3440-28-6
Betamipron( —— )
Catalog No. M14175 CAS No. 3440-28-6
Betamipron is a chemical compound which is used together with panipenem to inhibit panipenem uptake into the renal tubule and prevent nephrotoxicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 37 | In Stock |
|
| 1G | 56 | In Stock |
|
Biological Information
-
Product NameBetamipron
-
NoteResearch use only, not for human use.
-
Brief DescriptionBetamipron is a chemical compound which is used together with panipenem to inhibit panipenem uptake into the renal tubule and prevent nephrotoxicity.
-
DescriptionBetamipron is a chemical compound which is used together with panipenem to inhibit panipenem uptake into the renal tubule and prevent nephrotoxicity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number3440-28-6
-
Formula Weight193.2
-
Molecular FormulaC10H11NO3
-
Purity>98% (HPLC)
-
SolubilityEthanol: 39 mg/mL (201.86 mM); DMSO: 39 mg/mL (201.86 mM)
-
SMILESOC(=O)CCNC(=O)C1=CC=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ohashi N, et al. J Infect ChemOthers, 2005, 11(1), 24-3
molnova catalog
related products
-
TCS 1205
GABAA α2 agonist and GABAA α1 partial agonist.
-
β-Endorphin (30-31) ...
Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration.
-
(-)-Sesamin
(-)-Sesamin isolated from Asarum forbesii Maxim, is an isomer of Sesamin. Sesamin is a potent and selective delta 5 desaturase inhibitor in polyunsaturated fatty acid biosynthesis.
